The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN head and neck cancer practice guidelines. Available at: www.nccn.org. Accessed on February 19, 2005.
2.
VokesE.E., MaranW.J., MickR.Neoadjuvant and Adjuvant Methotrexate, Cisplatin, and Fluorocil in Multimodal Therapy of Head and Neck Cancer. J Clin Oncol.1989; 7(7): 838–845.
3.
VokesE.E., PanjeW.R., MickR.A Randomized Study Comparing Two Regimens of Neoadjuvant and Adjuvant Chemotherapy in Multimodal Therapy for Locally Advanced Head and Neck Cancer. Cancer.1990; 66: 206–213.
4.
VokesE.E., SchilskyR.L., ChoiK.E.A Randomized Study of Inpatient Versus Outpatient Continuous Infusion Chemotherapy for Patients With Locally Advanced Head and Neck Cancer. Cancer.1989; 63: 30–36.
5.
EnsleyJ., KishJ., TapazoglouE.An Intensive, Five Course, Alternating Combination Chemotherapy Induction Regimen Used in Patients With Advanced, Unresectable Head and Neck Cancer. J Clin Oncol.1988; 6(7): 1147–1153.
6.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
7.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56: 729–764.
8.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Available at: www.nccn.org. Accessed on February 19, 2005.
9.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17(9): 2971–2994.
10.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–158.
11.
KintzelP.E.Anticancer drug-induced kidney disorders - incidence, prevention and management. Drug Saf.2001; 24: 19–38.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol.2003; 30(4 Suppl 13):10–17.
16.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18(20): 3558–3585.
17.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
18.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–402.
19.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22: 2918–2926.
20.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
21.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 494–504.
22.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24(4): 969–989.
23.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic agents. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 483–493.
